Gut microbiome changes during abemaciclib in breast cancer
Part of Cancer, Skin clinical trials.
This study looks at how abemaciclib (Verzenio) affects the bacteria in your gut (the microbiome). If you have a certain type of breast cancer and are starting this treatment, researchers want to understand why it works the way it does.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have breast cancer that is hormone receptor-positive and HER2-negative.
- You are about to start or have just started taking abemaciclib (Verzenio) as part of your standard treatment.
- You are able to take care of yourself (ECOG performance status 0-2).
- If you could become pregnant, you agree to use birth control during the study and for 3 months after.
- You do not have a chronic bowel condition like inflammatory bowel disease, short bowel syndrome, or chronic diarrhea.
- You are not allergic or intolerant to resistant starch (a type of fiber).
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how the bacteria in your digestive system may affect side effects from abemaciclib, a hormone-based breast cancer drug. By collecting stool samples, researchers hope to understand which patients might experience fewer problems and how to better manage treatment.
This trial is for people with hormone receptor-positive breast cancer who are at high risk of recurrence. It looks at how the body processes abemaciclib, a targeted therapy, and whether that affects severe diarrhea, a common side effect.
This study tests whether women with early-stage HR+/HER2- breast cancer can safely take a higher dose of the drug abemaciclib (Verzenio) after surgery. The goal is to keep the treatment as strong as possible while managing side effects.
This trial tests whether the drug abemaciclib can help women with hormone receptor-positive, HER2-negative breast cancer who still have signs of cancer DNA in their blood after standard treatment. It aims to prevent a future return of the cancer.
This trial tests whether a special probiotic supplement (good bacteria) can reduce belly discomfort caused by abemaciclib, a hormone therapy drug for early breast cancer. You would take the supplement alongside your cancer treatment to see if it helps with stomach side effects.
This trial tests if adding abemaciclib (a targeted pill) to standard chemotherapy before surgery can shrink HR+/HER2- breast cancer and allow less extensive surgery. It also aims to see if a genetic test (Oncotype DX) can help guide treatment decisions.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.